Literature DB >> 2769516

Immunologic therapy for hemolytic-uremic syndrome.

D V Milford, C M Taylor, P E Rose, T C Roy, B Rowe.   

Abstract

Entities:  

Mesh：

Year:  1989        PMID： 2769516     DOI： 10.1016/s0022-3476(89)80872-8

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


× No keyword cloud information.
  3 in total

1.  Shiga toxins 1 and 2 translocate differently across polarized intestinal epithelial cells.

Authors:  B P Hurley; M Jacewicz; C M Thorpe; L L Lincicome; A J King; G T Keusch; D W Acheson
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

2.  Evidence that verotoxins (Shiga-like toxins) from Escherichia coli bind to P blood group antigens of human erythrocytes in vitro.

Authors:  M Bitzan; S Richardson; C Huang; B Boyd; M Petric; M A Karmali
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

3.  The use of intravenous gammaglobulin in the treatment of typical hemolytic uremic syndrome.

Authors:  W L Robson; G H Fick; T Jadavji; A K Leung
Journal:  Pediatr Nephrol       Date:  1991-05       Impact factor: 3.714
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.